Not Yet Recruiting
PHASE3
INTERVENTIONAL
NCT07232719
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
Interventions
Name:
Retatrutide
Type:
DRUG
Description:
Administered SC
Name:
Placebo
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Percent Change from Baseline in Body Weight
TimeFrame:
Baseline, Week 56
Description:
Trial Information
NCT ID
NCT07232719
Status
Not Yet Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025